The urticaria drugs market will register a CAGR of over 10% by 2022

Thursday, March 21, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 20, 2019 /PRNewswire/ -- About this marketUrticaria is a vastly prevalent disorder resulting in high

medical consultations globally. The increase in risk factors for urticaria like latent infectious, chronic inflammatory diseases, autoreactivity and alcohol consumption. Though the incident is increasing, and it is negatively impacting the quality of
life of the people, most patients are undertreated due to challenges in affordability of drugs and low access to healthcare due to social stigma. Technavio's analysts have predicted that the urticaria drugs market will register a CAGR of over 10% by 2022.Read the full report: https://www.reportlinker.com/p05745761/?utm_source=PRN Market OverviewGuidelines for management of urticaria patientsThe management guidelines include clinical classification, etiology, investigations, diagnosis, treatment guidance along with special sections on children suffering from urticaria and the use of antihistamines in pregnant women or breastfeeding women.High cost of urticaria managementThe high medication costs along with the indirect costs are expected to put low- income patients at danger for suboptimal treatment and an increased burden due to poorly controlled disease.For the detailed list of factors that will drive and challenge the growth of the urticaria drugs market during the 2018-2022, view our report.Competitive LandscapeThe global urticaria drugs market is moderately concentrated and the market being in a growth phase, the competition among companies is intense. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Read the full report: https://www.reportlinker.com/p05745761/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-urticaria-drugs-market-will-register-a-cagr-of-over-10-by-2022-300815810.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store